$0.60 EPS Expected for Abbott Laboratories (ABT)

June 19, 2017 - By Vivian Park

 $0.60 EPS Expected for Abbott Laboratories (ABT)
Investors sentiment increased to 1.01 in 2016 Q4. Its up 0.05, from 0.96 in 2016Q3. It increased, as 83 investors sold Abbott Laboratories shares while 496 reduced holdings. 103 funds opened positions while 481 raised stakes. 1.06 billion shares or 1.63% more from 1.04 billion shares in 2016Q3 were reported.
Delaware-based Brandywine Tru has invested 5.88% in Abbott Laboratories (NYSE:ABT). Gam Hldg Ag stated it has 614,517 shares. Advisor Prtn Ltd Liability Com holds 0.25% or 21,625 shares in its portfolio. Roundview Limited Liability has 6,195 shares for 0.08% of their portfolio. Alley Co Ltd Limited Liability Company accumulated 104,928 shares or 1.77% of the stock. Alexandria Capital Ltd Company invested 0.11% in Abbott Laboratories (NYSE:ABT). Tiaa Cref Investment Mngmt Ltd Liability stated it has 10.77M shares or 0.31% of all its holdings. Garrison owns 73,996 shares or 1.77% of their US portfolio. Excalibur Mgmt reported 28,890 shares stake. Country Club Trust Communications Na has 6,764 shares for 0.04% of their portfolio. Schroder Inv Management Gru holds 0.01% or 77,744 shares. Glenmede Tru Na has 1.71 million shares for 0.36% of their portfolio. Kidder Stephen W stated it has 135,335 shares. Moreover, Girard Prtnrs Ltd has 0.98% invested in Abbott Laboratories (NYSE:ABT) for 87,566 shares. Hall Laurie J Trustee holds 66,351 shares or 1.73% of its portfolio.

Since December 20, 2016, it had 1 buy, and 19 selling transactions for $8.43 million activity. Fussell Stephen R bought $497,394 worth of Abbott Laboratories (NYSE:ABT) on Tuesday, January 31. On Tuesday, February 28 Salvadori Daniel Gesua Sive sold $93,776 worth of Abbott Laboratories (NYSE:ABT) or 2,066 shares. Watkin Jared sold $24,965 worth of Abbott Laboratories (NYSE:ABT) on Friday, February 17. $86,068 worth of stock was sold by Mason Heather L on Tuesday, February 28. BIRD ROGER sold $595,273 worth of stock. ALLEN HUBERT L sold $38,569 worth of stock or 857 shares. Shares for $14,349 were sold by NATH DEEPAK S..

Analysts await Abbott Laboratories (NYSE:ABT) to report earnings on July, 19. They expect $0.60 earnings per share, up 9.09 % or $0.05 from last year’s $0.55 per share. ABT’s profit will be $1.04 billion for 20.23 P/E if the $0.60 EPS becomes a reality. After $0.48 actual earnings per share reported by Abbott Laboratories for the previous quarter, Wall Street now forecasts 25.00 % EPS growth. About 1.38 million shares traded. Abbott Laboratories (NYSE:ABT) has risen 15.90% since June 19, 2016 and is uptrending. It has underperformed by 0.80% the S&P500.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

Among 17 analysts covering Abbott Laboratories (NYSE:ABT), 9 have Buy rating, 0 Sell and 8 Hold. Therefore 53% are positive. Abbott Laboratories had 51 analyst reports since July 24, 2015 according to SRatingsIntel. Jefferies maintained the shares of ABT in report on Tuesday, September 13 with “Buy” rating. The rating was maintained by BTIG Research on Saturday, August 29 with “Buy”. The stock has “Buy” rating by Jefferies on Friday, June 16. The firm earned “Buy” rating on Thursday, August 4 by Jefferies. Barclays Capital upgraded Abbott Laboratories (NYSE:ABT) on Wednesday, October 7 to “Overweight” rating. The stock of Abbott Laboratories (NYSE:ABT) has “Buy” rating given on Thursday, July 23 by Stifel Nicolaus. The company was maintained on Thursday, August 27 by Wells Fargo. The stock of Abbott Laboratories (NYSE:ABT) earned “Overweight” rating by Barclays Capital on Thursday, April 20. The rating was downgraded by BMO Capital Markets on Tuesday, March 14 to “Market Perform”. The rating was maintained by Cowen & Co with “Buy” on Monday, April 17.

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The company has market cap of $84.41 billion. The Firm operates through four divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. It has a 53.9 P/E ratio. The Company’s Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

More notable recent Abbott Laboratories (NYSE:ABT) news were published by: Finance.Yahoo.com which released: “Abbott Laboratories at 52-Week High on Product Line, Buyouts” on June 05, 2017, also Nasdaq.com with their article: “Adage Capital Partners Gp Llc Buys Deere, Puma Biotechnology Inc, Abbott …” published on June 05, 2017, Finance.Yahoo.com published: “Abbott Laboratories Up on EPD & Buyouts, Pediatric Weak” on June 15, 2017. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: Seekingalpha.com and their article: “Abbott Hangs On For New HeartMate Model Amid Recall” published on May 31, 2017 as well as Seekingalpha.com‘s news article titled: “This May Be The Start Of Abbott Laboratories’ Upside Trajectory For 2017” with publication date: May 30, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: